YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from ...
The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T ...
In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...
Gilead is soaring to new heights in the CAR-T therapeutics sector, acquiring in vivo cell therapy specialist Interius BioTherapeutics via its subsidiary Kite for $350m. The deal will integrate ...
Some of my most satisfying moments as a clinician over the past 50 years have been when I conducted in vivo behavior therapy exposure and practice with patients suffering from anxiety and phobias.
With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
The Chosun Ilbo on MSN
In vivo CAR-T therapy transforms cancer treatment
A method called "in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)" that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...
A team of scientists from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has identified a unique window shortly after birth in which circulating blood stem cells can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results